Efficient Nanovaccine Delivery in Cancer Immunotherapy
Vaccines hold tremendous potential for cancer immunotherapy by treating the immune system. Subunit vaccines, including molecular adjuvants and cancer-associated antigens or cancer-specific neoantigens, can elicit potent antitumor immunity. However, subunit vaccines have shown limited clinical benefi...
Gespeichert in:
| Veröffentlicht in: | ACS nano 2017-03, Vol.11 (3), p.2387-2392 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2392 |
|---|---|
| container_issue | 3 |
| container_start_page | 2387 |
| container_title | ACS nano |
| container_volume | 11 |
| creator | Zhu, Guizhi Zhang, Fuwu Ni, Qianqian Niu, Gang Chen, Xiaoyuan |
| description | Vaccines hold tremendous potential for cancer immunotherapy by treating the immune system. Subunit vaccines, including molecular adjuvants and cancer-associated antigens or cancer-specific neoantigens, can elicit potent antitumor immunity. However, subunit vaccines have shown limited clinical benefit in cancer patients, which is in part attributed to inefficient vaccine delivery. In this Perspective, we discuss vaccine delivery by synthetic nanoparticles or naturally derived nanoparticles for cancer immunotherapy. Nanovaccines can efficiently codeliver adjuvants and multiepitope antigens into lymphoid organs and into antigen-presenting cells, and the intracellular release of vaccine and cross-presentation of antigens can be fine-tuned via nanovaccine engineering. Aside from peptide antigens, antigen-encoding mRNA for cancer immunotherapy delivered by nanovaccine will also be discussed. |
| doi_str_mv | 10.1021/acsnano.7b00978 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1876494243</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1876494243</sourcerecordid><originalsourceid>FETCH-LOGICAL-a333t-37fdd0d0f91cbbae0865f73e2070ef9a56c03cba04a4f029335860ea9699d9843</originalsourceid><addsrcrecordid>eNp1kDFPwzAQRi0EolCY2VBGJJT2Eid2PKJSoFIFC0hsluOcRarEKXZSqf8eo4ZuTHfD-57uPkJuEpglkCZzpb1VtpvxEkDw4oRcJIKyGAr2eXrc82RCLr3fAOS84OycTNIi5Zxl7IKwpTG1rtH20WsQ7ZTWtcXoEZt6h24f1TZaKKvRRau2HWzXf6FT2_0VOTOq8Xg9zin5eFq-L17i9dvzavGwjhWltI8pN1UFFRiR6LJUGO7KDaeYAgc0QuVMA9WlgkxlBlJBaV4wQCWYEJUoMjoldwfv1nXfA_petrXX2DTKYjd4mYR_MpGlGQ3o_IBq13nv0Mitq1vl9jIB-VuWHMuSY1khcTvKh7LF6sj_tROA-wMQknLTDc6GX__V_QB1TXTH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1876494243</pqid></control><display><type>article</type><title>Efficient Nanovaccine Delivery in Cancer Immunotherapy</title><source>ACS Publications</source><source>MEDLINE</source><creator>Zhu, Guizhi ; Zhang, Fuwu ; Ni, Qianqian ; Niu, Gang ; Chen, Xiaoyuan</creator><creatorcontrib>Zhu, Guizhi ; Zhang, Fuwu ; Ni, Qianqian ; Niu, Gang ; Chen, Xiaoyuan</creatorcontrib><description>Vaccines hold tremendous potential for cancer immunotherapy by treating the immune system. Subunit vaccines, including molecular adjuvants and cancer-associated antigens or cancer-specific neoantigens, can elicit potent antitumor immunity. However, subunit vaccines have shown limited clinical benefit in cancer patients, which is in part attributed to inefficient vaccine delivery. In this Perspective, we discuss vaccine delivery by synthetic nanoparticles or naturally derived nanoparticles for cancer immunotherapy. Nanovaccines can efficiently codeliver adjuvants and multiepitope antigens into lymphoid organs and into antigen-presenting cells, and the intracellular release of vaccine and cross-presentation of antigens can be fine-tuned via nanovaccine engineering. Aside from peptide antigens, antigen-encoding mRNA for cancer immunotherapy delivered by nanovaccine will also be discussed.</description><identifier>ISSN: 1936-0851</identifier><identifier>EISSN: 1936-086X</identifier><identifier>DOI: 10.1021/acsnano.7b00978</identifier><identifier>PMID: 28277646</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Animals ; Cancer Vaccines - immunology ; Drug Carriers - chemistry ; Drug Delivery Systems ; Humans ; Nanoparticles - chemistry ; Neoplasms - immunology ; Neoplasms - therapy</subject><ispartof>ACS nano, 2017-03, Vol.11 (3), p.2387-2392</ispartof><rights>Copyright © 2017 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a333t-37fdd0d0f91cbbae0865f73e2070ef9a56c03cba04a4f029335860ea9699d9843</citedby><cites>FETCH-LOGICAL-a333t-37fdd0d0f91cbbae0865f73e2070ef9a56c03cba04a4f029335860ea9699d9843</cites><orcidid>0000-0002-1928-3472 ; 0000-0002-9622-0870</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsnano.7b00978$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsnano.7b00978$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28277646$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Guizhi</creatorcontrib><creatorcontrib>Zhang, Fuwu</creatorcontrib><creatorcontrib>Ni, Qianqian</creatorcontrib><creatorcontrib>Niu, Gang</creatorcontrib><creatorcontrib>Chen, Xiaoyuan</creatorcontrib><title>Efficient Nanovaccine Delivery in Cancer Immunotherapy</title><title>ACS nano</title><addtitle>ACS Nano</addtitle><description>Vaccines hold tremendous potential for cancer immunotherapy by treating the immune system. Subunit vaccines, including molecular adjuvants and cancer-associated antigens or cancer-specific neoantigens, can elicit potent antitumor immunity. However, subunit vaccines have shown limited clinical benefit in cancer patients, which is in part attributed to inefficient vaccine delivery. In this Perspective, we discuss vaccine delivery by synthetic nanoparticles or naturally derived nanoparticles for cancer immunotherapy. Nanovaccines can efficiently codeliver adjuvants and multiepitope antigens into lymphoid organs and into antigen-presenting cells, and the intracellular release of vaccine and cross-presentation of antigens can be fine-tuned via nanovaccine engineering. Aside from peptide antigens, antigen-encoding mRNA for cancer immunotherapy delivered by nanovaccine will also be discussed.</description><subject>Animals</subject><subject>Cancer Vaccines - immunology</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Delivery Systems</subject><subject>Humans</subject><subject>Nanoparticles - chemistry</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><issn>1936-0851</issn><issn>1936-086X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kDFPwzAQRi0EolCY2VBGJJT2Eid2PKJSoFIFC0hsluOcRarEKXZSqf8eo4ZuTHfD-57uPkJuEpglkCZzpb1VtpvxEkDw4oRcJIKyGAr2eXrc82RCLr3fAOS84OycTNIi5Zxl7IKwpTG1rtH20WsQ7ZTWtcXoEZt6h24f1TZaKKvRRau2HWzXf6FT2_0VOTOq8Xg9zin5eFq-L17i9dvzavGwjhWltI8pN1UFFRiR6LJUGO7KDaeYAgc0QuVMA9WlgkxlBlJBaV4wQCWYEJUoMjoldwfv1nXfA_petrXX2DTKYjd4mYR_MpGlGQ3o_IBq13nv0Mitq1vl9jIB-VuWHMuSY1khcTvKh7LF6sj_tROA-wMQknLTDc6GX__V_QB1TXTH</recordid><startdate>20170328</startdate><enddate>20170328</enddate><creator>Zhu, Guizhi</creator><creator>Zhang, Fuwu</creator><creator>Ni, Qianqian</creator><creator>Niu, Gang</creator><creator>Chen, Xiaoyuan</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1928-3472</orcidid><orcidid>https://orcid.org/0000-0002-9622-0870</orcidid></search><sort><creationdate>20170328</creationdate><title>Efficient Nanovaccine Delivery in Cancer Immunotherapy</title><author>Zhu, Guizhi ; Zhang, Fuwu ; Ni, Qianqian ; Niu, Gang ; Chen, Xiaoyuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a333t-37fdd0d0f91cbbae0865f73e2070ef9a56c03cba04a4f029335860ea9699d9843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Cancer Vaccines - immunology</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Delivery Systems</topic><topic>Humans</topic><topic>Nanoparticles - chemistry</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Guizhi</creatorcontrib><creatorcontrib>Zhang, Fuwu</creatorcontrib><creatorcontrib>Ni, Qianqian</creatorcontrib><creatorcontrib>Niu, Gang</creatorcontrib><creatorcontrib>Chen, Xiaoyuan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>ACS nano</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Guizhi</au><au>Zhang, Fuwu</au><au>Ni, Qianqian</au><au>Niu, Gang</au><au>Chen, Xiaoyuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficient Nanovaccine Delivery in Cancer Immunotherapy</atitle><jtitle>ACS nano</jtitle><addtitle>ACS Nano</addtitle><date>2017-03-28</date><risdate>2017</risdate><volume>11</volume><issue>3</issue><spage>2387</spage><epage>2392</epage><pages>2387-2392</pages><issn>1936-0851</issn><eissn>1936-086X</eissn><abstract>Vaccines hold tremendous potential for cancer immunotherapy by treating the immune system. Subunit vaccines, including molecular adjuvants and cancer-associated antigens or cancer-specific neoantigens, can elicit potent antitumor immunity. However, subunit vaccines have shown limited clinical benefit in cancer patients, which is in part attributed to inefficient vaccine delivery. In this Perspective, we discuss vaccine delivery by synthetic nanoparticles or naturally derived nanoparticles for cancer immunotherapy. Nanovaccines can efficiently codeliver adjuvants and multiepitope antigens into lymphoid organs and into antigen-presenting cells, and the intracellular release of vaccine and cross-presentation of antigens can be fine-tuned via nanovaccine engineering. Aside from peptide antigens, antigen-encoding mRNA for cancer immunotherapy delivered by nanovaccine will also be discussed.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>28277646</pmid><doi>10.1021/acsnano.7b00978</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-1928-3472</orcidid><orcidid>https://orcid.org/0000-0002-9622-0870</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1936-0851 |
| ispartof | ACS nano, 2017-03, Vol.11 (3), p.2387-2392 |
| issn | 1936-0851 1936-086X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1876494243 |
| source | ACS Publications; MEDLINE |
| subjects | Animals Cancer Vaccines - immunology Drug Carriers - chemistry Drug Delivery Systems Humans Nanoparticles - chemistry Neoplasms - immunology Neoplasms - therapy |
| title | Efficient Nanovaccine Delivery in Cancer Immunotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T15%3A19%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficient%20Nanovaccine%20Delivery%20in%20Cancer%20Immunotherapy&rft.jtitle=ACS%20nano&rft.au=Zhu,%20Guizhi&rft.date=2017-03-28&rft.volume=11&rft.issue=3&rft.spage=2387&rft.epage=2392&rft.pages=2387-2392&rft.issn=1936-0851&rft.eissn=1936-086X&rft_id=info:doi/10.1021/acsnano.7b00978&rft_dat=%3Cproquest_cross%3E1876494243%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1876494243&rft_id=info:pmid/28277646&rfr_iscdi=true |